

What is claimed is:

1. An anticancer or an anti-metastatic agent for gene therapy containing a gene carrier or cells harboring human apolipoprotein(a) kringle KIV9-KIV10-
5 KV (LK68) or KV (LK8) gene as an effective ingredient

2. The agent according to claim 1, wherein the LK68 gene comprises a nucleotide sequence represented by SEQ. ID. No. 1.
10

3. The agent according to claim 1, wherein the gene carrier harboring the LK68 gene is a vector or a recombinant virus.

15 4. The agent according to claim 3, wherein the vector is selected from a group consisting of a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.

20 5. The agent according to claim 3, wherein the recombinant virus is selected from a group consisting of retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

25 6. The agent according to claim 1, wherein the

cells are selected from a group consisting of hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells.

5 7. The agent according to claim 1, wherein the gene carrier is selected from a group consisting of pSecTag-LK68, pLXSN-LK68, rAAV-LK68 and pAAV-LK68.

8. The agent according to claim 1, wherein the
10 LK8 gene comprises a nucleotide sequence represented by SEQ. ID. No. 2.

9. The agent according to claim 1, wherein the gene carrier harboring the LK8 gene is a vector or a
15 recombinant virus.

10. The agent according to claim 9, wherein the vector is selected from a group consisting of a linear DNA vector, a plasmid DNA vector and a recombinant
20 viral vector.

11. The agent according to claim 9, wherein the recombinant virus is selected from a group consisting of retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.
25

12. The agent according to claim 9, wherein the gene carrier is selected from a group consisting of pSecTag-LK8, pLXSN-LK8, rAAV-LK8 and pAAV-LK8.

5

13. The agent according to claim 3 or claim 9, wherein the vector is included by 0.05 ~ 500 mg.

14. The agent according to claim 3 or claim 9,
10 wherein the recombinant virus is included by $10^3 - 10^{12}$ IU.

15. The agent according to claim 1, wherein the cells are included by $10^3 - 10^8$ e.a.

15

16. The agent according to claim 1, wherein the cancer is selected from a group consisting of colon carcinoma, liver cancer, lung cancer, breast cancer, brain tumor, prostatic carcinoma, skin cancer, stomach
20 cancer, pancreas cancer, lymphoma, kidney cancer, ovarian cancer and metastatic tumor.

17. The agent according to claim 16, wherein the cancer is selected from a group consisting of colon
25 carcinoma, liver cancer, lymphoma or metastatic tumor.

18. A method for the prevention or the treatment
of a solid tumor, which includes a step of parenteral
administration of the agent for gene therapy of claim
5 1 to an individual.

19. The method according to claim 18, wherein
the prevention or the treatment of a solid tumor is
accomplished by the inhibition of the growth and the
10 metastasis of the solid tumor.

20. The method according to claim 18, wherein
the administration of a gene carrier harboring human
apolipoprotein(a) kringle KIV9-KIV10-KV(LK68) or
15 KV(LK8) gene is accomplished by a method selected
from a group consisting of chemical method, physical
method, conjugation using liposome, a method using
receptor and virus, etc.

20 21. The method according to claim 18, wherein
the administration is characterized by injecting cells
selected from a group consisting of hematopoietic stem
cells, dendritic cells, autologous tumor cells and
established tumor cells transfected with human
25 apolipoprotein(a) kringle KIV9-KIV10-KV(LK68) or

KV(LK8) gene to a patient.